The aim of the study was to evaluate concentrations of IL-17 in the serum and plaque scales of psoriatic patients. We analyzed their association with the clinical activity of the disease and with body mass index (BMI). Demographic data, medical history, serum, and scale from psoriatic plaques for assessment of IL-17 were collected from all the participants. The disease severity was assessed with PASI (Psoriasis Area and Severity Index), BSA (Body Surface Area), PGA (Physician Global Assessment), NAPSI (Nail Psoriasis Severity Index), and DLQI (Dermatology Quality of Life Index) scores. Obesity was diagnosed by calculating body mass index. Serum and scale concentration of IL-17 was determined with Human IL-17A High Sensitivity ELISA kit and Human IL-17 ELISA kit. In the psoriatic patients, BMI was statistically significantly higher than in the control group. Most of the patients presented BMI higher than normal. Our study confirms that overweight is a problem among psoriatic patients. A significant positive correlation between the IL-17 serum and scale concentrations and psoriasis severity indicates that IL-17 can be used as the marker of disease severity. More data from human studies can be crucial for understanding that relationship between IL-17, psoriasis, and obesity.

中文翻译：

---

银屑病患者血清和斑块量表中的IL-17A可作为疾病严重程度和肥胖症的潜在标志。

该研究的目的是评估银屑病患者血清和斑块量表中IL-17的浓度。我们分析了它们与疾病的临床活动以及体重指数（BMI）的关联。从所有参与者中收集了来自银屑病斑块的人口统计学数据，病史，血清和规模，以评估IL-17。疾病严重程度通过PASI（牛皮癣面积和严重程度指数），BSA（身体表面积），PGA（医师全球评估），NAPSI（指甲牛皮癣严重程度指数）和DLQI（皮肤病生活质量指数）评分进行评估。通过计算体重指数诊断出肥胖。用人IL-17A高灵敏度ELISA试剂盒和人IL-17 ELISA试剂盒测定IL-17的血清和规模浓度。在银屑病患者中 BMI在统计学上显着高于对照组。大多数患者的BMI高于正常水平。我们的研究证实，超重是银屑病患者的一个问题。IL-17血清和鳞片浓度与牛皮癣严重程度之间存在显着的正相关关系，表明IL-17可用作疾病严重程度的标志物。来自人类研究的更多数据对于了解IL-17，牛皮癣和肥胖之间的关系可能至关重要。